Vanda Pharmaceuticals (VNDA) Other Non-Current Liabilities (2012 - 2026)
Vanda Pharmaceuticals recorded quarterly Other Non-Current Liabilities of $10.1 million in Q1 2026, up 6.23% quarter-over-quarter from $9.5 million in Q4 2025, and up 9.54% year-over-year from $9.2 million in Q1 2025.
Vanda Pharmaceuticals' Other Non-Current Liabilities history runs 14 years deep, the most recent figure standing at $10.1 million for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 9.54% year-over-year to $10.1 million; the TTM figure through Mar 2026 stood at $10.1 million (up 9.54% YoY), while the FY2025 annual figure was $9.5 million, down 0.56% from the prior year.
- Other Non-Current Liabilities came in at $10.1 million for Q1 2026 at Vanda Pharmaceuticals, up from $9.5 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $11.0 million in Q3 2025 to a low of $1.0 million in Q1 2022.
- A 5-year average of $7.7 million and a median of $8.8 million in 2024 frame the typical range for Other Non-Current Liabilities.
- Across the five-year window, Other Non-Current Liabilities slumped 61.09% in 2022 and soared 540.08% in 2023, its largest moves.
- Vanda Pharmaceuticals' Other Non-Current Liabilities stood at $6.8 million in 2022, then gained by 29.81% to $8.8 million in 2023, then rose by 8.61% to $9.6 million in 2024, then fell by 0.56% to $9.5 million in 2025, then climbed by 6.23% to $10.1 million in 2026.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $10.1 million, $9.5 million, and $11.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Vanda Pharmaceuticals | 379.35 Mn | 177.04 Mn | 48.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.13 Mn |
| Dec 31, 2025 | 9.53 Mn |
| Sep 30, 2025 | 11.04 Mn |
| Jun 30, 2025 | 9.97 Mn |
| Mar 31, 2025 | 9.25 Mn |
| Dec 31, 2024 | 9.59 Mn |
| Sep 30, 2024 | 9.32 Mn |
| Jun 30, 2024 | 9.06 Mn |
| Mar 31, 2024 | 8.83 Mn |
| Dec 31, 2023 | 8.83 Mn |
| Sep 30, 2023 | 6.20 Mn |
| Jun 30, 2023 | 6.45 Mn |
| Mar 31, 2023 | 6.61 Mn |
| Dec 31, 2022 | 6.80 Mn |
| Sep 30, 2022 | 4.61 Mn |
| Jun 30, 2022 | 2.87 Mn |
| Mar 31, 2022 | 1.03 Mn |
| Dec 31, 2021 | 4.39 Mn |
| Sep 30, 2021 | 3.99 Mn |
| Jun 30, 2021 | 3.70 Mn |
| Mar 31, 2021 | 2.66 Mn |
| Dec 31, 2020 | 2.76 Mn |
| Sep 30, 2020 | 2.42 Mn |
| Jun 30, 2020 | 1.74 Mn |
| Mar 31, 2020 | 778,000.00 |
| Dec 31, 2019 | 843,000.00 |
| Sep 30, 2019 | 753,000.00 |
| Jun 30, 2019 | 221,000.00 |
| Mar 31, 2019 | 162,000.00 |
| Dec 31, 2018 | 3.69 Mn |
| Sep 30, 2018 | 4.28 Mn |
| Jun 30, 2018 | 4.77 Mn |
| Mar 31, 2018 | 4.22 Mn |
| Dec 31, 2017 | 3.68 Mn |
| Sep 30, 2017 | 3.70 Mn |
| Jun 30, 2017 | 3.82 Mn |
| Mar 31, 2017 | 3.61 Mn |
| Dec 31, 2016 | 3.72 Mn |
| Sep 30, 2016 | 3.60 Mn |
| Jun 30, 2016 | 3.66 Mn |
| Mar 31, 2016 | 3.69 Mn |
| Dec 31, 2015 | 3.71 Mn |
| Sep 30, 2015 | 3.72 Mn |
| Jun 30, 2015 | 3.75 Mn |
| Mar 31, 2015 | 4.38 Mn |
| Dec 31, 2014 | 3.10 Mn |
| Sep 30, 2014 | 113,000.00 |
| Jun 30, 2014 | 140,000.00 |
| Mar 31, 2012 | 278,000.00 |